Elevated DTYMK activity has been observed across several malignancies, encompassing breast cancer, adrenocortical carcinoma, renal clear cell carcinoma, bladder carcinoma, and thyroid cancer [42]. This evidence concerns the gene DTYMK and urinary bladder carcinoma.